Acute cardiotoxicity during capecitabine treatment:: A case report

被引：34

作者：

Bertolini, A

Fiumanò, M

Fusco, O

Muffatti, A

Scarinci, A

Pontiggia, G

Scopelliti, M

机构：

[1] Osped Sondrio, UO Oncol Med, Div Med Oncol, I-23100 Sondrio, Italy

[2] Osped Sondrio, Dept Cardiol, I-23100 Sondrio, Italy

来源：

TUMORI | 2001年 / 87卷 / 03期

关键词：

capecitabine; cardiotoxicity;

D O I：

10.1177/030089160108700317

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Capecitabine (Xeloda (R), Roche, Monza), a fluoropyrimidine carbamate, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumor. The drug has demonstrated activity in metastatic breast cancer, pancreatic cancer and colorectal cancer. In this case report the authors describe an unusually and reversible cardiac side effect which occurs to 39-year-old patient treated with capecitabine 2000 mg/m(2)/day for advanced gastric cancer. It is important to note that the safety data from clinical trials indicate that capecitabine has a toxicity profile typical of infused fluoropyrimidines. However, none of the studies described cardiac side effects.

引用

收藏

页码：200 / 206

页数：7

相关论文

共 33 条

[1] A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease [J].

Bajetta, E ;

Carnaghi, C ;

Somma, L ;

Stampino, CG .

TUMORI, 1996, 82 (05) :450-452

[2] Cardiotoxicity of the antiproliferative compound fluorouracil [J].

Becker, K ;

Erckenbrecht, JF ;

Häussinger, D ;

Frieling, T .

DRUGS, 1999, 57 (04) :475-484

[3]

Bertolini A, 1999, Minerva Cardioangiol, V47, P269

[4] Xeloda® in the treatment of metastatic breast cancer [J].

Blum, JL .

ONCOLOGY, 1999, 57 :16-20

[5] Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer [J].

Blum, JL ;

Jones, SE ;

Buzdar, AU ;

LoRusso, PM ;

Kuter, I ;

Vogel, C ;

Osterwalder, B ;

Burger, HU ;

Brown, CS ;

Griffin, T .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :485-493

[6]

BROWN KE, 2000, P ASCO, V19, pJ921

[7] Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine [J].

Budman, DR ;

Meropol, NJ ;

Reigner, B ;

Creaven, PJ ;

Lichtman, SM ;

Berghorn, E ;

Behr, J ;

Gordon, RJ ;

Osterwalder, B ;

Griffin, T .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1795-1802

[8] Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy [J].

Cardinale, D ;

Sandri, MT ;

Martinoni, A ;

Tricca, A ;

Civelli, M ;

Lamantia, G ;

Cinieri, S ;

Martinelli, G ;

Cipolla, CM ;

Fiorentini, C .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (02) :517-522

[9]

CARTWRIGHT T, 2000, P ASCO, V19, P1026

[10] Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: A report from the Italian group for the study of digestive tract cancer [J].

Cascinu, S ;

Labianca, R ;

Alessandroni, P ;

Marcellini, M ;

Silva, RR ;

Pancera, G ;

Testa, E ;

Martignoni, G ;

Barni, S ;

Frontini, L ;

Zaniboni, A ;

Luporini, G ;

Cellerino, R ;

Catalano, G .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (11) :3313-3319

← 1 2 3 4 →